Sumitomo Mitsui Trust Group
NKTR icon

Sumitomo Mitsui Trust Group’s Nektar Therapeutics NKTR Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-45,155
Closed -$12.3M – 1113
2019
Q3 		$12.3M Sell
45,155
-1,841
-4% -$675K 0.01% 708
2019
Q2 		$25.1M Buy
46,996
+1,504
+3% +$754K 0.02% 617
2019
Q1 		$22.9M Buy
45,492
+6,030
+15% +$3.57M 0.02% 609
2018
Q4 		$19.9M Buy
39,462
+2,768
+8% +$1.67M 0.02% 599
2018
Q3 		$33.6M Buy
36,694
+3,666
+11% +$3.13M 0.04% 505
2018
Q2 		$24.2M Buy
+33,028
New +$38.1M 0.03% 581

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group's NKTR Position: Q4 2019 in Review

Sumitomo Mitsui Trust Group sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 45,155 shares — an estimated $12.3M sold.

Sumitomo Mitsui Trust Group first reported a position in NKTR in Q2 2018 and held it in 6 quarters. The position peaked at $33.6M in Q3 2018. 280 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Sumitomo Mitsui Trust Group reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 45,155 Nektar Therapeutics shares in Q4 2019, an estimated $12.3M.
  • Sumitomo Mitsui Trust Group first reported a position in Nektar Therapeutics in Q2 2018 and held it in 6 quarters.
  • Sumitomo Mitsui Trust Group's Nektar Therapeutics position peaked at $33.6M in Q3 2018.
  • 280 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q4 2019, filed 31 Jan 2020.